Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Mangoceuticals (MGRX) Shares Outstanding (Weighted Average) (2023 - 2025)

Mangoceuticals' Shares Outstanding (Weighted Average) history spans 3 years, with the latest figure at $11.5 million for Q3 2025.

  • For Q3 2025, Shares Outstanding (Weighted Average) rose 472.25% year-over-year to $11.5 million; the TTM value through Sep 2025 reached $11.5 million, up 472.25%, while the annual FY2024 figure was $2.0 million, 84.23% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q3 2025 was $11.5 million at Mangoceuticals, up from $7.3 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $14.5 million in Q2 2023 and bottomed at $994897.0 in Q3 2023.
  • The 3-year median for Shares Outstanding (Weighted Average) is $2.0 million (2024), against an average of $5.3 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) tumbled 88.7% in 2024 before it skyrocketed 472.25% in 2025.
  • A 3-year view of Shares Outstanding (Weighted Average) shows it stood at $1.1 million in 2023, then soared by 84.23% to $2.0 million in 2024, then soared by 482.34% to $11.5 million in 2025.
  • Per Business Quant, the three most recent readings for MGRX's Shares Outstanding (Weighted Average) are $11.5 million (Q3 2025), $7.3 million (Q2 2025), and $4.6 million (Q1 2025).